Tag Archives: Biotechnology Industry

Biotech Stocks: Perspective in a Bull Market

biotech companies

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Will We Ever Have Genetically Modified Meat?

LBS-graphic-200x100 copy

Currently, there are no genetically engineered animals sold for human consumption on the market, reports Popular Science. As you might have guessed, the lack of genetically modified meat on the market isn’t because of a lack of technology or safety; it’s because of the politics. GM foods are deeply unpopular as of now, and GM food animals are especially so. After reading an article concerning GM animals from The Scientist showing how effective they can be, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Some People Get it, and Some Just Don’t

admin-ajax (2)

As a communications director in the agriculture industry, I have spent two decades using fact-based talking points while industry opponents can say whatever will make a headline. It’s frustrating, but we labor on because we believe that what we do somehow helps farmers. And if we can help farmers, we can help keep America’s food supply safe, affordable and the envy of the world. Holly Spangler, an ag communicator and Illinois farmer, clearly understands this Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Debunking the Biotech Bubble Talk

Chart

The Nasdaq Biotechnology Index (NBI) has been on a wild ride in 2014 with a 20 percent gain in the first two months, a 24 percent drop from late February to mid-April, and a rebound of 16 percent off April lows by early June. This recent sell-off follows a 130 percent gain over the last three years and the debut of 100 biotech IPOs, leading some investors to ask if the recent sell-off is the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

San Francisco Business Times: Two JOBS Acts are better than one

scientist-eyedropper

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding the Jumpstart Our Business Startups Act (JOBS) Act for giving emerging biotech companies a much-needed boost. As Hastings points out, 80-plus companies will have gone public in the last two years with the help of the JOBS Act. As the biotech industry gathers in San Diego next month for the 2014 BIO International Convention, several CEOs in attendance will no Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,